-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Bentuximab vitoxin is an effective anti-CD30 antibody drug conjugate, which has been approved for the treatment of adult classic Hodgkin's lymphoma (HL).
Lymphoma in children
This open-label, single-arm, multi-center trial included patients (age ≤ 18 years) with stage IIB, IIIB, or IV classic HL.
Of the 77 patients who participated in the study, 27 (35%) achieved complete remission at ERA and did not receive radiation therapy.
In summary, the results of the study show that the integration of Bentuximab Vidotin into the first-line treatment of children with high-risk HL is highly tolerated by the children, which is conducive to significantly reducing the dose of radiotherapy and can be achieved Good curative effect.
Original source:
Monika L Metzger, et al.
ncbi.
nlm.
nih.
gov/33826362/" target="_blank" rel="noopener">Excellent Outcome for Pediatric Patients With High- Risk Hodgkin Lymphoma Treated With Brentuximab Vedotin and Risk-Adapted Residual Node Radiation in this message